NEW YORK, May 15 (Reuters) - Another setback for Amgen Inc.'s anemia-drug franchise sent shares of the No. 1 biotechnology company spiraling down as much as 6.6 percent on Tuesday to a 2-1/2-year low as more analysts cut their ratings on the beaten-down stock.
